Oncogene-independent resistance in Philadelphia chromosome - positive (Ph(+)) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway

Tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, and ponatinib have significantly improved the life expectancy of Philadelphia chromosome-positive (Ph(+)) acute lymphocytic leukemia (ALL) patients; however, resistance to TKIs remains a major clinical challenge. Point mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Mian, Afsar Ali, Zafar, Usva, Ahmed, Syed Muhammad Areeb, Ottmann, Oliver Gerhard, Lalani, El-Nasir M A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368770/
https://www.ncbi.nlm.nih.gov/pubmed/34403880
http://dx.doi.org/10.1016/j.neo.2021.07.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368770/
https://www.ncbi.nlm.nih.gov/pubmed/34403880
http://dx.doi.org/10.1016/j.neo.2021.07.009

Ejemplares similares